Condition: Solid Tumor, Adult · Microsatellite Stable Colorectal Cancer · Head and Neck Squamous Cell Carcinoma · Sponsor: KaliVir Immunotherapeutics
VET3-TGI is an oncolytic immunotherapy designed to treat advanced cancers. VET3-TGI has not been given to human patients yet, and the current study is designed to find a safe and effective dose of VET3-TGI when administered by direct injection into tumor(s) (called an intratumoral injection) or when given intravenously (into the vein) both alone and in combination with atezolizumab in patients with solid tumors (STEALTH-001).
This description comes directly from the study's public registry record.
Adina Pelusio · +13057722084 · clinops@kalivir.com
James Burke, MD · clinops@kalivir.com
Always discuss trial participation with your own doctor first.
| USC/Norris Comprehensive Cancer Center | Los Angeles, California, United States | Recruiting |
| UC Irvine Health | Orange, California, United States | Recruiting |
| University of Miami | Miami, Florida, United States | Recruiting |
| Community Health Network | Indianapolis, Indiana, United States | Recruiting |
| UPMC- Hillman Cancer Center | Pittsburgh, Pennsylvania, United States | Recruiting |
| Mary Crowley Cancer Research | Dallas, Texas, United States | Recruiting |
| University of Texas MD Anderson Cancer Center | Houston, Texas, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06444815